AGCO fined Richard Moreau and Sylvain Filion for 10 years and $40,000 for DPO in racehorses

TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) — To protect the welfare and safety of horses and protect the integrity of horse racing, the Alcohol and Gaming Commission of Ontario (AGCO) has imposed fines and suspensions on Standardbred trainer Richard. Moreau and driver Sylvain Filion. Both were found to be in violation of AGCO’s rules Standardbred Racing Rules.

AGCO has obtained a Certificate of Analysis confirming the presence of non-therapeutic drug darpoetin alpha For the FUNTIME BAYAMA horse collected on June 10, 2024 within the scope of (DPO) Non-Competitive Testing Program. DPO is a banned non-therapeutic, performance-enhancing substance that adversely affects racehorses and the integrity of racing.

For these violations, Moreau was suspended for 10 years, from July 23, 2024 to July 23, 2034. Filion was suspended for 10 years, from October 31, 2024 to October 31, 2034. Both licensees were also fined $40,000.

The decisions followed his immediate suspension Moreau, 24 July 2024. As a result of the investigation into the circumstances resulting from the positive test, it was revealed that Filion also served as the horse’s trainer. Both Filion and Moreau are held responsible for DPO’s presence in FUNTIME BAYAMA.

Horses owned by Moreau and/or Filion are ineligible to race during the 10-year suspension period pursuant to Standardbred Rule 6.13.01. Horses trained by Moreau and/or Filion are also ineligible but are determined by AGCO Racing Officials in accordance with Standardbred Rule 26.08 and Directive No. If approved under 2-2008, he could be released or sold to another trainer.

A licensed horse racing participant, Race Rules Has the right to appeal AGCO’s decision Horse Racing Appeals Panel (HRAP) It is an independent judicial body tasked with hearing appeals against decisions.

Quotation

“AGCO is committed to protecting the health and welfare of racehorses in Ontario and preserving the fairness and integrity of racing. “Performance-enhancing substances have no use in sport and their administration can have serious consequences for licensees.”

Dr. Karin Schnarr, Editor-in-Chief and CEO – AGCO

Rule Violations

AGCO took this regulatory action in accordance with the following rules:

Official Decisions

The Story Continues